https://news.medxy.ai/stratifying-risk-for-further-retinal-intervention-after-laser-retinopexy-the-impact-of-cumulative-clinical-factors/Medxy AIen2026-09-15T08:50:56-07:00Stratifying Risk for Further Retinal Intervention After Laser Retinopexy: The Impact of Cumulative Clinical Factors https://news.medxy.ai/zh/74133-2/Medxy AIzh2026-09-15T08:50:25-07:00微型单视（Mini-monovision）与正视状态下屈光型扩展景深人工晶状体（EDOF IOL）的视觉功能 https://news.medxy.ai/ja/extended-depth-focus-iol/Medxy AIja2026-09-15T08:50:04-07:00ミニモノビジョンと正視でみる屈折型拡張焦点深度IOLの視機能：包括的レビュー https://news.medxy.ai/vi/74128-2/Medxy AIvi2026-09-15T08:49:41-07:00Chức năng thị giác của thủy tinh thể nhân tạo (IOL) khúc xạ mở rộng độ sâu tiêu cự khi sử dụng phương pháp Mini-monovision và trạng thái chính thị https://news.medxy.ai/visual-performance-of-a-refractive-extended-depth-of-field-intraocular-lens-in-monovision-and-emmetropic-settings-a-comprehensive-review/Medxy AIen2026-09-15T08:49:20-07:00Visual Performance of a Refractive Extended Depth of Field Intraocular Lens in Monovision and Emmetropic Settings: A Comprehensive Review https://news.medxy.ai/zh/parotidectomy-botox/Medxy AIzh2026-09-15T08:48:29-07:00腮腺切除术中注射A型肉毒毒素：减少术后唾液囊肿的回顾性队列分析 https://news.medxy.ai/ja/botulinum-toxin-salivary-cyst/Medxy AIja2026-09-15T08:48:13-07:00耳下腺摘出術後の唾液瘤予防を目指した術中ボツリヌス毒素投与：後ろ向きコホート解析 https://news.medxy.ai/vi/botulinum-toxin-sialocele/Medxy AIvi2026-09-15T08:47:54-07:00Tiêm độc tố botulinum trong mổ để giảm sialocele sau phẫu thuật cắt tuyến mang tai: Phân tích đoàn hệ hồi cứu https://news.medxy.ai/intraoperative-botulinum-toxin-injection-to-reduce-postoperative-sialocele-after-parotidectomy-a-retrospective-cohort-analysis/Medxy AIen2026-09-15T08:47:35-07:00Intraoperative Botulinum Toxin Injection to Reduce Postoperative Sialocele After Parotidectomy: A Retrospective Cohort Analysis https://news.medxy.ai/zh/female-throat-cancer/Medxy AIzh2026-09-15T08:46:56-07:00女性喉癌治疗结局多中心回顾性分析 https://news.medxy.ai/ja/74115-2/Medxy AIja2026-09-15T08:46:42-07:00女性の喉頭癌治療成績に関する多施設共同後ろ向き解析 https://news.medxy.ai/vi/laryngeal-cancer-treatment/Medxy AIvi2026-09-15T08:46:25-07:00Kết cục điều trị ung thư thanh quản ở bệnh nhân nữ: Phân tích hồi cứu đa trung tâm https://news.medxy.ai/outcomes-of-laryngeal-carcinoma-treatment-in-female-patients-a-multicenter-retrospective-analysis/Medxy AIen2026-09-15T08:46:11-07:00Outcomes of Laryngeal Carcinoma Treatment in Female Patients: A Multicenter Retrospective Analysis https://news.medxy.ai/ja/appendiceal-abscess-diagnosis-2/Medxy AIja2026-09-15T08:45:38-07:00虫垂膿瘍の画像診断と治療経路：2025年イタリア・コンセンサスから読み解く実践ポイント https://news.medxy.ai/vi/appendiceal-abscess-diagnosis/Medxy AIvi2026-09-15T08:45:11-07:00Áp-xe ruột thừa dưới góc nhìn chẩn đoán hình ảnh: cách phân loại và đường đi chẩn đoán từ đồng thuận Ý 2025 https://news.medxy.ai/zh/appendiceal-abscess-imaging/Medxy AIzh2026-09-15T08:44:44-07:00阑尾脓肿的影像分型与诊断路径：2025年意大利共识的临床要点 https://news.medxy.ai/imaging-guided-classification-and-diagnostic-pathways-for-appendiceal-abscesses-practical-takeaways-from-the-2025-italian-consensus/Medxy AIen2026-09-15T08:44:21-07:00Imaging-Guided Classification and Diagnostic Pathways for Appendiceal Abscesses: Practical Takeaways from the 2025 Italian Consensus https://news.medxy.ai/zh/aortic-aneurysm-safety/Medxy AIzh2026-09-15T08:43:24-07:0090岁高龄患者接受血管内主动脉瘤修复术的安全性评估：一项风险校正分析 https://news.medxy.ai/ja/endovascular-aortic-aneurysm-safety/Medxy AIja2026-09-15T08:43:09-07:0090歳以上患者における血管内大動脈瘤修復術の安全性評価：リスク調整解析 https://news.medxy.ai/vi/aortic-aneurysm-repair-safety/Medxy AIvi2026-09-15T08:42:52-07:00Đánh giá độ an toàn của sửa chữa phình động mạch chủ bằng can thiệp nội mạch ở người 90 tuổi trở lên: Phân tích hiệu chỉnh theo nguy cơ https://news.medxy.ai/evaluating-endovascular-aortic-aneurysm-repair-safety-in-nonagenarians-a-risk-adjusted-analysis/Medxy AIen2026-09-15T08:42:35-07:00Evaluating Endovascular Aortic Aneurysm Repair Safety in Nonagenarians: A Risk-Adjusted Analysis https://news.medxy.ai/zh/pancreatic-cancer-5year-survival/Medxy AIzh2026-09-15T08:41:59-07:00局限性胰腺导管腺癌新辅助治疗后手术的真实5年生存结局 https://news.medxy.ai/ja/74099-2/Medxy AIja2026-09-15T08:41:44-07:00局所膵管腺癌に対する術前治療後の手術における実際の5年生存成績 https://news.medxy.ai/vi/survival-5-years/Medxy AIvi2026-09-15T08:41:25-07:00Sống còn thực tế 5 năm sau điều trị tân bổ trợ và phẫu thuật ở ung thư biểu mô tuyến ống tụy khu trú https://news.medxy.ai/real-world-five-year-survival-after-neoadjuvant-therapy-and-surgery-in-localized-pancreatic-ductal-adenocarcinoma/Medxy AIen2026-09-15T08:41:07-07:00Real-World Five-Year Survival After Neoadjuvant Therapy and Surgery in Localized Pancreatic Ductal Adenocarcinoma https://news.medxy.ai/zh/surgical-quality-ratios/Medxy AIzh2026-09-15T08:40:34-07:00重新审视外科质量指标：老年急诊普通外科结局中的手术治疗与非手术治疗比 https://news.medxy.ai/ja/surgical-quality-indicators/Medxy AIja2026-09-15T08:40:19-07:00外科品質指標を再考する：高齢者緊急一般外科転帰における手術的治療／非手術的治療比の意義 https://news.medxy.ai/vi/surgical-quality-measure/Medxy AIvi2026-09-15T08:39:59-07:00Suy nghĩ lại về thước đo chất lượng phẫu thuật: Vai trò của tỷ lệ điều trị phẫu thuật trên điều trị không phẫu thuật trong kết cục phẫu thuật tổng quát cấp cứu ở người cao tuổi https://news.medxy.ai/rethinking-surgical-quality-metrics-the-role-of-operative-to-nonoperative-management-ratio-in-elderly-emergency-general-surgery-outcomes/Medxy AIen2026-09-15T08:39:40-07:00Rethinking Surgical Quality Metrics: The Role of Operative-to-Nonoperative Management Ratio in Elderly Emergency General Surgery Outcomes https://news.medxy.ai/ja/masld-colorectal-cancer-risk-2/Medxy AIja2026-09-15T08:39:03-07:00MASLDで結腸直腸癌リスクは上がるのか？ 国際コンセンサスが示す臨床の要点 https://news.medxy.ai/vi/masld-cancer-risk/Medxy AIvi2026-09-15T08:38:38-07:00Đồng thuận quốc tế mới: nguy cơ ung thư đại trực tràng trong MASLD — bác sĩ lâm sàng cần biết gì https://news.medxy.ai/zh/masld-colorectal-cancer-risk/Medxy AIzh2026-09-15T08:38:14-07:00最新国际共识：MASLD中的结直肠癌风险——临床医生需要了解什么 https://news.medxy.ai/colorectal-cancer-risk/Medxy AIen2026-09-15T08:37:51-07:00New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know https://news.medxy.ai/zh/global-gut-brain-burden/Medxy AIzh2026-09-15T08:36:49-07:00全球肠-脑互动障碍负担：Rome V 与 Rome IV 标准的流行病学对照 https://news.medxy.ai/ja/dgbi-global-burden/Medxy AIja2026-09-15T08:36:32-07:00Rome Vで見えたDGBIの世界的負担：Rome IVとの比較でわかる最新知見 https://news.medxy.ai/vi/global-gut-brain-disorders/Medxy AIvi2026-09-15T08:36:13-07:00Gánh nặng toàn cầu của các rối loạn tương tác ruột–não: So sánh tiêu chuẩn Rome V và Rome IV https://news.medxy.ai/global-burden-of-disorders-of-gut-brain-interaction-insights-from-rome-v-versus-rome-iv-criteria/Medxy AIen2026-09-15T08:35:56-07:00Global Burden of Disorders of Gut-Brain Interaction: Insights from Rome V Versus Rome IV Criteria https://news.medxy.ai/zh/74068-2/Medxy AIzh2026-09-15T08:35:22-07:00远端及中等管径血管闭塞性卒中的早期再通：替奈普酶与阿替普酶的比较 https://news.medxy.ai/ja/early-recanalization/Medxy AIja2026-09-15T08:35:04-07:00遠位・中等大血管閉塞脳梗塞における早期再開通：テネクテプラーゼ vs アルテプラーゼ https://news.medxy.ai/vi/74064-2/Medxy AIvi2026-09-15T08:34:45-07:00Tái thông mạch sớm trong đột quỵ do tắc mạch máu đoạn xa và mạch máu cỡ trung bình: So sánh Tenecteplase và Alteplase https://news.medxy.ai/early-recanalization-in-distal-and-medium-vessel-occlusion-strokes-tenecteplase-vs-alteplase/Medxy AIen2026-09-15T08:34:27-07:00Early Recanalization in Distal and Medium Vessel Occlusion Strokes: Tenecteplase vs Alteplase https://news.medxy.ai/zh/pediatric-stroke-mri/Medxy AIzh2026-09-15T08:33:49-07:00儿童动脉缺血性卒中中的血管壁MRI：诊断与预后新视角 https://news.medxy.ai/ja/pediatric-arterial-ischemic-stroke-mri/Medxy AIja2026-09-15T08:33:35-07:00小児動脈性虚血性脳卒中における血管壁MRI：診断と予後を読み解く https://news.medxy.ai/vi/mra-stroke-children/Medxy AIvi2026-09-15T08:33:19-07:00Chụp cộng hưởng từ thành mạch trong đột quỵ thiếu máu cục bộ do động mạch ở trẻ em: giá trị chẩn đoán và tiên lượng https://news.medxy.ai/vessel-wall-mri-in-pediatric-arterial-ischemic-stroke-insights-into-diagnosis-and-prognosis/Medxy AIen2026-09-15T08:33:01-07:00Vessel Wall MRI in Pediatric Arterial Ischemic Stroke: Insights into Diagnosis and Prognosis https://news.medxy.ai/zh/levodopa-parkinsons-freezing/Medxy AIzh2026-09-15T08:32:24-07:00重新审视左旋多巴在帕金森病冻结步态中的作用：基于NS-Park与PPMI队列的研究洞见 https://news.medxy.ai/ja/levodopa-parkinson-frozen-steps/Medxy AIja2026-09-15T08:32:08-07:00パーキンソン病のすくみ足におけるレボドパの位置づけを再考する：NS-ParkおよびPPMIコホートからの知見 https://news.medxy.ai/vi/levodopa-freezing-gait-parkinson/Medxy AIvi2026-09-15T08:31:52-07:00Tái đánh giá vai trò của levodopa đối với freezing of gait ở bệnh nhân Parkinson: phân tích từ hai đoàn hệ NS-Park và PPMI https://news.medxy.ai/levodopa-freezing-gait/Medxy AIen2026-09-15T08:31:34-07:00Reevaluating Levodopa’s Role in Freezing of Gait Among Parkinson’s Disease Patients: Insights from NS-Park and PPMI Cohorts https://news.medxy.ai/zh/mri-lacunar-stroke-metrics/Medxy AIzh2026-09-15T08:30:58-07:00MRI确诊腔隙性卒中的代谢特征与因果标志物：来自观察性研究和孟德尔随机化分析的证据 https://news.medxy.ai/ja/mri-lacunar-stroke/Medxy AIja2026-09-15T08:30:42-07:00MRI確認ラクナ脳梗塞における代謝シグネチャーと因果マーカー：観察研究とMendelian randomization解析からの知見 https://news.medxy.ai/vi/74036-2/Medxy AIvi2026-09-15T08:30:23-07:00Dấu ấn chuyển hóa và dấu ấn nhân quả trong nhồi máu não ổ khuyết được xác định bằng MRI https://news.medxy.ai/metabolic-signatures-and-causal-markers-in-mri-confirmed-lacunar-stroke-insights-from-observational-and-mendelian-randomization-analyses/Medxy AIen2026-09-15T08:30:04-07:00Metabolic Signatures and Causal Markers in MRI-Confirmed Lacunar Stroke: Insights from Observational and Mendelian Randomization Analyses https://news.medxy.ai/zh/thalamic-bioenergetics-dpn/Medxy AIzh2026-09-15T08:29:26-07:00疼痛性糖尿病周围神经病变中丘脑生物能量学与神经功能得以保留：来自双模磁共振波谱的启示 https://news.medxy.ai/ja/74030-2/Medxy AIja2026-09-15T08:29:09-07:00疼痛性糖尿病性末梢神経障害における視床の生体エネルギーと神経機能の保持 https://news.medxy.ai/vi/diabetic-peripheral-neuropathy/Medxy AIvi2026-09-15T08:28:49-07:00Đau thần kinh ngoại biên do đái tháo đường: Đồi thị được bảo tồn về chức năng nơron và sinh năng lượng qua MRS kép https://news.medxy.ai/preserved-thalamic-bioenergetics-and-neuronal-function-in-painful-diabetic-peripheral-neuropathy-insights-from-dual-magnetic-resonance-spectroscopy/Medxy AIen2026-09-15T08:28:32-07:00Preserved Thalamic Bioenergetics and Neuronal Function in Painful Diabetic Peripheral Neuropathy: Insights from Dual Magnetic Resonance Spectroscopy https://news.medxy.ai/zh/cortisol-severity-impact/Medxy AIzh2026-09-15T08:27:58-07:00高皮质醇血症严重程度对库欣综合征肾上腺皮质癌结局的影响 https://news.medxy.ai/ja/cushing-syndrome-adrenal-cancer/Medxy AIja2026-09-15T08:27:43-07:00クッシング症候群を伴う副腎皮質癌における高コルチゾール血症の重症度と転帰への影響 https://news.medxy.ai/vi/cortisol-adrenal-cancer/Medxy AIvi2026-09-15T08:27:27-07:00Mức độ tăng cortisol máu ảnh hưởng thế nào đến tiên lượng của u vỏ thượng thận ác tính kèm hội chứng Cushing? https://news.medxy.ai/hypercortisolism-impact/Medxy AIen2026-09-15T08:27:11-07:00Impact of Hypercortisolism Severity on Outcomes in Adrenocortical Carcinoma with Cushing’s Syndrome https://news.medxy.ai/zh/raas-medication-management/Medxy AIzh2026-09-15T08:26:37-07:00原醛症诊断前，RAAS调节药物该停吗？如何在准确性与可行性之间权衡 https://news.medxy.ai/ja/stop-raas-before-aldosteronism/Medxy AIja2026-09-15T08:26:21-07:00原発性アルドステロン症の診断前にRAAS修飾薬は中止すべきか――精度と実用性の両立を考える https://news.medxy.ai/vi/raas-inhibitor-discontinuation/Medxy AIvi2026-09-15T08:26:01-07:00Ngừng thuốc điều biến RAAS trước chẩn đoán cường aldosteron nguyên phát: Cân bằng giữa độ chính xác và tính thực tiễn https://news.medxy.ai/balancing-accuracy-and-practicality-should-raas-modifying-drugs-be-withdrawn-in-primary-aldosteronism-diagnosis/Medxy AIen2026-09-15T08:25:44-07:00Balancing Accuracy and Practicality: Should RAAS-Modifying Drugs Be Withdrawn in Primary Aldosteronism Diagnosis? https://news.medxy.ai/zh/glp-1ra-diabetes-gi-risk/Medxy AIzh2026-09-15T08:25:07-07:00GLP-1RA治疗的2型糖尿病患者：不同阿片类药物的胃肠道风险差异 https://news.medxy.ai/ja/opioid-gut-risk-diabetes/Medxy AIja2026-09-15T08:24:51-07:00GLP-1RA治療中の2型糖尿病患者におけるオピオイドの消化管リスク比較：薬剤別解析 https://news.medxy.ai/vi/opioid-digestive-risk-diabetes/Medxy AIvi2026-09-15T08:24:34-07:00Nguy cơ tiêu hóa khác nhau giữa các opioid ở bệnh nhân đái tháo đường típ 2 đang điều trị GLP-1RA: phân tích so sánh https://news.medxy.ai/differential-gastrointestinal-risks-of-opioids-in-type-2-diabetes-patients-on-glp-1ra-therapy-a-comparative-analysis/Medxy AIen2026-09-15T08:24:18-07:00Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative Analysis https://news.medxy.ai/zh/cardiac-resynchronization/Medxy AIzh2026-09-15T08:23:46-07:00心脏再同步化治疗：从代谢组学看心力衰竭的改善机制 https://news.medxy.ai/ja/73992-2/Medxy AIja2026-09-15T08:23:32-07:00心臓再同期療法：メタボロミクスからみた心不全の改善メカニズム https://news.medxy.ai/vi/73990-2/Medxy AIvi2026-09-15T08:23:16-07:00Liệu pháp tái đồng bộ tim: Những hiểu biết từ nghiên cứu chuyển hóa học về sự cải thiện tình trạng suy tim https://news.medxy.ai/cardiac-resynchronization-therapy-metabolomic-insights-into-heart-failure-improvement/Medxy AIen2026-09-15T08:22:58-07:00Cardiac Resynchronization Therapy: Metabolomic Insights into Heart Failure Improvement https://news.medxy.ai/zh/lmna-afib-risk/Medxy AIzh2026-09-15T08:22:26-07:00扩张型心肌病中房颤风险为何因基因而异？——SHaRe Registry 研究揭示 LMNA 突变的关键作用 https://news.medxy.ai/ja/af-risk-genotype/Medxy AIja2026-09-15T08:22:12-07:00拡張型心筋症における心房細動リスクは遺伝子型で異なる：SHaRe Registryからの知見 https://news.medxy.ai/vi/atrial-fibrillation-risk/Medxy AIvi2026-09-15T08:21:55-07:00Nguy cơ và tác động của rung nhĩ ở bệnh cơ tim giãn theo kiểu gen: Phát hiện từ SHaRe Registry https://news.medxy.ai/genotype-dependent-risk-and-impact-of-atrial-fibrillation-in-dilated-cardiomyopathy-insights-from-the-share-registry/Medxy AIen2026-09-15T08:21:38-07:00Genotype-Dependent Risk and Impact of Atrial Fibrillation in Dilated Cardiomyopathy: Insights from the SHaRe Registry https://news.medxy.ai/zh/silent-liver-signals/Medxy AIzh2026-09-15T08:21:06-07:00无声的肝脏信号：亚临床肝病如何推高心血管风险——一项大型前瞻性研究的启示 https://news.medxy.ai/ja/liver-damage-heart-risk/Medxy AIja2026-09-15T08:20:49-07:00見過ごされがちな肝障害が心血管リスクを押し上げる：大規模前向き研究が示す新たな知見 https://news.medxy.ai/vi/subclinical-liver-disease/Medxy AIvi2026-09-15T08:20:32-07:00Bệnh gan dưới lâm sàng: “tác nhân thầm lặng” làm gia tăng nguy cơ tim mạch từ một nghiên cứu tiến cứu quy mô lớn https://news.medxy.ai/subclinical-liver-disease-as-a-silent-driver-of-cardiovascular-risk-insights-from-a-large-scale-prospective-study/Medxy AIen2026-09-15T08:20:16-07:00Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective Study https://news.medxy.ai/zh/night-lighting-effects/Medxy AIzh2026-09-15T08:19:43-07:00夜间灯光并非无害：夜间光暴露如何影响心脏结构、功能及心血管风险 https://news.medxy.ai/ja/night-light-heart-impact/Medxy AIja2026-09-15T08:19:24-07:00夜の光は心臓にどう影響するのか――夜間光暴露が心臓構造・機能と心血管リスクに及ぼす影響 https://news.medxy.ai/vi/73967-2/Medxy AIvi2026-09-15T08:19:04-07:00Ánh sáng ban đêm ảnh hưởng thế nào đến tim? — Tác động của việc tiếp xúc với ánh sáng ban đêm đối với cấu trúc, chức năng tim và nguy cơ tim mạch https://news.medxy.ai/illuminating-the-night-how-nighttime-light-exposure-impacts-cardiac-structure-function-and-cardiovascular-risk/Medxy AIen2026-09-15T08:18:46-07:00Illuminating the Night: How Nighttime Light Exposure Impacts Cardiac Structure, Function, and Cardiovascular Risk https://news.medxy.ai/zh/wildfire-smoke-cardiovascular-risk/Medxy AIzh2026-09-15T07:37:52-07:00长期暴露于野火烟雾 PM2.5：美国老年人心血管风险不容忽视 https://news.medxy.ai/ja/wildfire-smoke-heart-risk/Medxy AIja2026-09-15T07:37:34-07:00米国高齢者における長期的な山火事煙PM2.5曝露がもたらす心血管への負荷 https://news.medxy.ai/vi/pm25-wildfire-exposure/Medxy AIvi2026-09-15T07:37:13-07:00Phơi Nhiễm PM2.5 Từ Khói Cháy Rừng Kéo Dài: Gánh Nặng Tim Mạch Ở Người Cao Tuổi Hoa Kỳ https://news.medxy.ai/unveiling-the-cardiovascular-toll-of-long-term-wildfire-smoke-pm2-5-exposure-in-older-americans/Medxy AIen2026-09-15T07:36:52-07:00Unveiling the Cardiovascular Toll of Long-Term Wildfire Smoke PM2.5 Exposure in Older Americans https://news.medxy.ai/zh/polygenic-risk-coronary-atherosclerosis/Medxy AIzh2026-09-15T07:36:08-07:00PROACT临床试验中基于多基因风险的亚临床冠状动脉粥样硬化检出与治疗：一种基因型优先的精准预防策略 https://news.medxy.ai/ja/polygenic-risk-detection/Medxy AIja2026-09-15T07:35:47-07:00PROACT試験におけるポリジェニックリスクを基盤とした無症候性冠動脈アテローム性動脈硬化症の検出と治療：genotype-first precision prevention戦略 https://news.medxy.ai/vi/coronary-atherosclerosis-treatment/Medxy AIvi2026-09-15T07:35:24-07:00Phát hiện và điều trị xơ vữa động mạch vành tiền lâm sàng dựa trên nguy cơ đa gen trong các thử nghiệm lâm sàng PROACT: tiếp cận phòng ngừa chính xác theo kiểu genotype-first https://news.medxy.ai/polygenic-risk-based-detection-and-treatment-of-subclinical-coronary-atherosclerosis-in-the-proact-clinical-trials-a-genotype-first-precision-prevention-approach/Medxy AIen2026-09-15T07:35:03-07:00Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials: A Genotype-First Precision Prevention Approach https://news.medxy.ai/zh/liver-cancer-boundary-2/Medxy AIzh2026-09-14T10:40:30-07:00绘制肝癌隐匿边界：NCACC揭示驱动肿瘤侵袭的罕见cIgG+上皮细胞 https://news.medxy.ai/ja/liver-cancer-boundary/Medxy AIja2026-09-14T10:40:14-07:00肝臓がんの見えない境界を地図化：NCACCが浸潤を駆動する稀少cIgG陽性上皮細胞を発見 https://news.medxy.ai/vi/liver-cancer-cells/Medxy AIvi2026-09-14T10:39:53-07:00Vẽ lại những vùng khuất của ung thư gan: NCACC phát hiện các tế bào biểu mô cIgG+ hiếm gặp thúc đẩy xâm lấn khối u https://news.medxy.ai/mapping-liver-cancers-hidden-frontiers-ncacc-uncovers-rare-cigg-epithelial-cells-driving-tumor-invasion/Medxy AIen2026-09-14T10:39:37-07:00Mapping Liver Cancer’s Hidden Frontiers: NCACC Uncovers Rare cIgG+ Epithelial Cells Driving Tumor Invasion https://news.medxy.ai/zh/msh3-mlh3-mutations-2/Medxy AIzh2026-09-14T10:39:04-07:00MSH3与MLH3胚系突变可作为抑癌因子，经由ID4高突变特征升高结直肠癌风险 https://news.medxy.ai/ja/msh3-mlh3-cancer-risk/Medxy AIja2026-09-14T10:38:46-07:00MSH3・MLH3 生殖細胞系列変異は大腸癌リスクを高める腫瘍抑制因子か：変異シグネチャー ID4 に注目して https://news.medxy.ai/vi/msh3-mlh3-mutations/Medxy AIvi2026-09-14T10:38:25-07:00Đột biến dòng mầm MSH3 và MLH3: gen ức chế u làm tăng nguy cơ ung thư đại trực tràng với chữ ký tăng đột biến ID4 https://news.medxy.ai/germline-msh3-and-mlh3-mutations-as-tumor-suppressors-elevating-colorectal-cancer-risk-via-hypermutation-signature-id4/Medxy AIen2026-09-14T10:38:05-07:00Germline MSH3 and MLH3 Mutations as Tumor Suppressors Elevating Colorectal Cancer Risk via Hypermutation Signature ID4 https://news.medxy.ai/zh/moyamoya-disease/Medxy AIzh2026-09-14T10:37:25-07:00出血型烟雾病的自然病程与治疗结局：来自中国大型队列的研究启示 https://news.medxy.ai/ja/moyamoya-disease-2/Medxy AIja2026-09-14T10:37:05-07:00出血型モヤモヤ病の自然経過と治療成績：大規模中国コホートから見えた知見 https://news.medxy.ai/vi/73690-2/Medxy AIvi2026-09-14T10:36:44-07:00Diễn tiến tự nhiên và kết quả điều trị bệnh Moyamoya thể xuất huyết https://news.medxy.ai/natural-history-and-treatment-outcomes-in-hemorrhagic-moyamoya-disease-insights-from-a-large-chinese-cohort/Medxy AIen2026-09-14T10:36:24-07:00Natural History and Treatment Outcomes in Hemorrhagic Moyamoya Disease: Insights from a Large Chinese Cohort https://news.medxy.ai/zh/spontaneous-csf-leak/Medxy AIzh2026-09-14T10:35:47-07:00自发性脊髓脑脊液漏所致双臂性肌萎缩：临床特征与手术结局解析 https://news.medxy.ai/ja/spinal-csf-leak-study/Medxy AIja2026-09-14T10:35:24-07:00脊髄性髄液漏に伴う両上肢萎縮性筋力低下の解明：臨床所見と手術成績 https://news.medxy.ai/vi/bilateral-arm-spasticity/Medxy AIvi2026-09-14T10:34:57-07:00Teo cơ hai tay trong rò dịch não tủy cột sống tự phát: Nhận diện lâm sàng và kết quả phẫu thuật https://news.medxy.ai/unraveling-bibrachial-amyotrophy-in-spontaneous-spinal-csf-leaks-clinical-insights-and-surgical-outcomes/Medxy AIen2026-09-14T10:34:32-07:00Unraveling Bibrachial Amyotrophy in Spontaneous Spinal CSF Leaks: Clinical Insights and Surgical Outcomes https://news.medxy.ai/zh/stroke-risk-biomarkers-2/Medxy AIzh2026-09-14T10:33:55-07:00循环代谢物有望成为卒中风险预测新型生物标志物：BiomarCaRE项目研究启示 https://news.medxy.ai/ja/stroke-risk-biomarkers/Medxy AIja2026-09-14T10:33:38-07:00脳卒中リスク予測を支える新規バイオマーカー：循環代謝産物に注目したBiomarCaRE研究 https://news.medxy.ai/vi/circulating-metabolite-biomarker/Medxy AIvi2026-09-14T10:33:14-07:00Chất chuyển hóa tuần hoàn: biomarker mới nổi giúp dự báo nguy cơ đột quỵ từ BiomarCaRE https://news.medxy.ai/circulating-metabolites-as-emerging-biomarkers-for-stroke-risk-prediction-insights-from-the-biomarcare-project/Medxy AIen2026-09-14T10:32:53-07:00Circulating Metabolites as Emerging Biomarkers for Stroke Risk Prediction: Insights from the BiomarCaRE Project https://news.medxy.ai/zh/high-res-tera-analysis/Medxy AIzh2026-09-14T10:30:51-07:00高分辨率断连组分析提升基底动脉闭塞的预后预测，并辅助取栓决策 https://news.medxy.ai/ja/high-res-disconnectome-predicts-outcome/Medxy AIja2026-09-14T10:30:24-07:00高解像度disconnectomeが予後予測精度を高め、脳底動脈閉塞の血栓回収療法判断を支援する https://news.medxy.ai/vi/73670-2/Medxy AIvi2026-09-14T10:30:02-07:00Bản đồ kết nối bị gián đoạn độ phân giải cao giúp nâng cao độ chính xác trong tiên lượng và định hướng quyết định lấy huyết khối ở bệnh nhân tắc động mạch nền https://news.medxy.ai/high-resolution-disconnectome-enhances-prognostic-accuracy-and-guides-thrombectomy-decisions-in-basilar-artery-occlusion/Medxy AIen2026-09-14T10:29:44-07:00High-Resolution Disconnectome Enhances Prognostic Accuracy and Guides Thrombectomy Decisions in Basilar Artery Occlusion https://news.medxy.ai/zh/age-neurodegeneration-bell-palsy/Medxy AIzh2026-09-14T10:29:06-07:00年龄与神经变性协同影响贝尔麻痹恢复：临床意义与启示 https://news.medxy.ai/ja/aging-neurodegeneration-bell-palsy/Medxy AIja2026-09-14T10:28:50-07:00高齢と神経変性の相乗効果がBell麻痺の回復を左右する：臨床的含意 https://news.medxy.ai/vi/age-neurodegeneration-bells-palsy/Medxy AIvi2026-09-14T10:28:31-07:00Ảnh hưởng cộng hưởng của tuổi tác và thoái hóa thần kinh lên hồi phục Bell’s palsy: Ý nghĩa lâm sàng https://news.medxy.ai/synergistic-impact-of-age-and-nerve-degeneration-on-bells-palsy-recovery-clinical-implications/Medxy AIen2026-09-14T10:28:12-07:00Synergistic Impact of Age and Nerve Degeneration on Bell’s Palsy Recovery: Clinical Implications https://news.medxy.ai/zh/genetics-thyroid-nodules/Medxy AIzh2026-09-14T10:27:23-07:00揭开家族性甲状腺滤泡结节性疾病的遗传复杂性 https://news.medxy.ai/ja/genetic-diversity-thyroid/Medxy AIja2026-09-14T10:27:00-07:00家族性甲状腺濾胞性結節性疾患に潜む遺伝的多様性を読み解く https://news.medxy.ai/vi/genetic-complexity-thyroid-disease/Medxy AIvi2026-09-14T10:26:39-07:00Giải mã tính phức tạp di truyền trong bệnh tuyến giáp dạng nhân nang có tính gia đình https://news.medxy.ai/unraveling-genetic-complexity-in-familial-thyroid-follicular-nodular-disease/Medxy AIen2026-09-14T10:26:15-07:00Unraveling Genetic Complexity in Familial Thyroid Follicular Nodular Disease https://news.medxy.ai/zh/perioperative-resuscitation-mortality/Medxy AIzh2026-09-14T10:25:37-07:00围手术期复苏状态限制与术后早期死亡：一项多中心回顾性队列研究的启示 https://news.medxy.ai/ja/perioperative-code-status-impact/Medxy AIja2026-09-14T10:25:17-07:00周術期コードステータス制限は術後早期死亡にどう影響するか：多施設後ろ向きコホート研究からの知見 https://news.medxy.ai/vi/surgery-complications/Medxy AIvi2026-09-14T10:24:56-07:00Hạn chế code status quanh phẫu thuật và tử vong sớm sau mổ: Những phát hiện từ nghiên cứu đoàn hệ hồi cứu đa trung tâm https://news.medxy.ai/perioperative-code-status-limitations-and-early-postoperative-mortality-insights-from-a-multicenter-retrospective-cohort-study/Medxy AIen2026-09-14T10:24:35-07:00Perioperative Code Status Limitations and Early Postoperative Mortality: Insights from a Multicenter Retrospective Cohort Study https://news.medxy.ai/zh/genetic-impact-diabetes/Medxy AIzh2026-09-14T10:23:59-07:00全胰切除联合胰岛自体移植后糖尿病结局的遗传影响 https://news.medxy.ai/ja/73633-2/Medxy AIja2026-09-14T10:23:41-07:00全膵切除術および膵島自家移植後の糖尿病転帰に対する遺伝的影響 https://news.medxy.ai/vi/genetics-diabetes-outcome/Medxy AIvi2026-09-14T10:23:17-07:00Di truyền ảnh hưởng thế nào đến kết cục đái tháo đường sau cắt toàn bộ tụy kèm ghép tự thân đảo tụy? https://news.medxy.ai/genetic-influences-on-diabetes-outcomes-after-total-pancreatectomy-with-islet-autotransplantation/Medxy AIen2026-09-14T10:22:58-07:00Genetic Influences on Diabetes Outcomes After Total Pancreatectomy with Islet Autotransplantation https://news.medxy.ai/zh/anti-inflammatory-diabetes-risk/Medxy AIzh2026-09-14T10:22:21-07:00常见抗炎药或可降低2型糖尿病患者危及视力的糖尿病视网膜病变风险 https://news.medxy.ai/ja/diabetic-retinopathy-risk-2/Medxy AIja2026-09-14T10:22:01-07:002型糖尿病における視機能を脅かす糖尿病網膜症のリスク低下と関連する一般的抗炎症薬 https://news.medxy.ai/vi/anti-inflammatory-drugs-diabetic-retinopathy/Medxy AIvi2026-09-14T10:21:38-07:00Các thuốc kháng viêm thường dùng có liên quan đến giảm nguy cơ bệnh võng mạc đái tháo đường đe dọa thị lực ở đái tháo đường típ 2 https://news.medxy.ai/common-anti-inflammatory-drugs-linked-to-lower-risk-of-vision-threatening-diabetic-retinopathy-in-type-2-diabetes/Medxy AIen2026-09-14T10:21:15-07:00Common Anti-Inflammatory Drugs Linked to Lower Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes https://news.medxy.ai/zh/episiotomy-types-risk/Medxy AIzh2026-09-14T10:20:31-07:00手术阴道助产中侧切类型对肛门括约肌损伤风险的影响 https://news.medxy.ai/ja/73617-2/Medxy AIja2026-09-14T10:20:13-07:00介助経腟分娩における会陰切開の種類が肛門括約筋損傷のリスクに及ぼす影響 https://news.medxy.ai/vi/episiotomy-type-anal-injury-risk/Medxy AIvi2026-09-14T10:19:55-07:00Loại rạch tầng sinh môn ảnh hưởng thế nào đến nguy cơ chấn thương cơ thắt hậu môn trong sinh ngả âm đạo có can thiệp tại Hoa Kỳ https://news.medxy.ai/impact-of-episiotomy-type-on-anal-sphincter-injury-risk-during-operative-vaginal-delivery-in-the-u-s/Medxy AIen2026-09-14T10:19:36-07:00Impact of Episiotomy Type on Anal Sphincter Injury Risk During Operative Vaginal Delivery in the U.S. https://news.medxy.ai/zh/preventive-mesh-implantation/Medxy AIzh2026-09-14T09:49:47-07:00预防性网片植入可显著降低肝胆胰手术后切口疝风险 https://news.medxy.ai/ja/incisional-hernia-prevention/Medxy AIja2026-09-14T09:49:30-07:00予防的メッシュ留置で肝胆膵手術後の切開ヘルニアリスクを大幅に低減 https://news.medxy.ai/vi/mesh-backup-reduces-hernia-risk/Medxy AIvi2026-09-14T09:49:12-07:00Đặt mesh dự phòng giúp giảm đáng kể nguy cơ thoát vị vết mổ sau phẫu thuật gan-mật-tụy https://news.medxy.ai/prophylactic-mesh-placement-significantly-reduces-incisional-hernia-risk-after-hepatobiliopancreatic-surgery/Medxy AIen2026-09-14T09:48:53-07:00Prophylactic Mesh Placement Significantly Reduces Incisional Hernia Risk After Hepatobiliopancreatic Surgery https://news.medxy.ai/zh/appendiceal-cancer-risk/Medxy AIzh2026-09-14T09:48:19-07:00局限性阑尾腺癌的复发风险评估与辅助化疗作用 https://news.medxy.ai/ja/appendiceal-adenocarcinoma-risk/Medxy AIja2026-09-14T09:48:02-07:00局所性虫垂腺癌における再発リスクと術後補助化学療法の意義を検証する https://news.medxy.ai/vi/recurrence-risk-chemotherapy-appendiceal/Medxy AIvi2026-09-14T09:47:42-07:00Đánh giá nguy cơ tái phát và vai trò của hóa trị bổ trợ trong ung thư biểu mô tuyến ruột thừa khu trú https://news.medxy.ai/evaluating-relapse-risks-and-the-role-of-adjuvant-chemotherapy-in-localized-appendiceal-adenocarcinoma/Medxy AIen2026-09-14T09:47:22-07:00Evaluating Relapse Risks and the Role of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma https://news.medxy.ai/zh/73480-2/Medxy AIzh2026-09-14T09:46:39-07:00推进 SGLT 抑制剂在 1 型糖尿病患者心肾保护中应用的机遇与挑战 https://news.medxy.ai/ja/sglt-in-type-1-diabetes/Medxy AIja2026-09-14T09:46:20-07:001型糖尿病におけるSGLT阻害薬の心腎保護活用を前進させる：機会と課題 https://news.medxy.ai/vi/sglt-inhibitors-heart-kidney/Medxy AIvi2026-09-14T09:45:58-07:00Mở rộng ứng dụng thuốc ức chế SGLT để bảo vệ tim và thận trong đái tháo đường type 1: Cơ hội và thách thức https://news.medxy.ai/advancing-sglt-inhibitor-use-for-heart-and-kidney-protection-in-type-1-diabetes-opportunities-and-challenges/Medxy AIen2026-09-14T09:45:37-07:00Advancing SGLT Inhibitor Use for Heart and Kidney Protection in Type 1 Diabetes: Opportunities and Challenges https://news.medxy.ai/zh/beta-cell-dysfunction-prediction/Medxy AIzh2026-09-14T09:44:41-07:00β细胞功能障碍可提升单一自身抗体阳性个体1型糖尿病进展预测能力 https://news.medxy.ai/ja/beta-cell-dysfunction-prediabetes/Medxy AIja2026-09-14T09:44:24-07:00単一自己抗体陽性者における1型糖尿病進行予測を高めるβ細胞機能障害 https://news.medxy.ai/vi/beta-cell-dysfunction-diabetes/Medxy AIvi2026-09-14T09:44:04-07:00Rối loạn chức năng tế bào β giúp dự báo tốt hơn tiến triển đái tháo đường typ 1 ở người chỉ dương tính với một tự kháng thể https://news.medxy.ai/beta-cell-dysfunction/Medxy AIen2026-09-14T09:43:44-07:00β-Cell Dysfunction Enhances Prediction of Type 1 Diabetes Progression in Individuals with Single Autoantibody Positivity https://news.medxy.ai/zh/hidden-high-risk-phenotype/Medxy AIzh2026-09-14T09:41:58-07:00借助异常检测模型揭示切除后胰腺实性假乳头状肿瘤中的隐匿高风险表型 https://news.medxy.ai/ja/high-risk-phenotype/Medxy AIja2026-09-14T09:41:40-07:00異常検出モデルで明らかにする、切除後solid pseudopapillary tumorに潜む高リスク表現型 https://news.medxy.ai/vi/hidden-high-risk-phenotypes/Medxy AIvi2026-09-14T09:41:23-07:00Phát hiện các kiểu hình nguy cơ cao ẩn giấu trong u nguyên bào giả nhú đặc tụy đã cắt bỏ bằng mô hình phát hiện bất thường https://news.medxy.ai/unveiling-hidden-high-risk-phenotypes-in-resected-solid-pseudopapillary-tumors-using-anomaly-detection-models/Medxy AIen2026-09-14T09:41:03-07:00Unveiling Hidden High-Risk Phenotypes in Resected Solid Pseudopapillary Tumors Using Anomaly-Detection Models https://news.medxy.ai/zh/esophageal-cancer-treatment/Medxy AIzh2026-09-14T09:40:28-07:00老年食管鳞状细胞癌如何权衡疗效与安全性：新辅助免疫放化疗与免疫化疗的比较 https://news.medxy.ai/ja/esophageal-cancer-treatment-2/Medxy AIja2026-09-14T09:40:10-07:00高齢食道扁平上皮癌における有効性と安全性の両立：術前免疫化学放射線療法と免疫化学療法の比較 https://news.medxy.ai/zh/lipid-metabolism-pah/Medxy AIzh2026-09-14T09:40:06-07:00脂质代谢谱揭示后毛细血管性与联合前后毛细血管性肺动脉高压的病理生理差异 https://news.medxy.ai/vi/immunotherapy-esophageal-cancer/Medxy AIvi2026-09-14T09:39:47-07:00Cân bằng giữa hiệu quả và an toàn: Hóa xạ trị miễn dịch tân bổ trợ so với hóa trị miễn dịch ở ung thư biểu mô tế bào vảy thực quản người cao tuổi https://news.medxy.ai/ja/lipid-metabolism-differences/Medxy AIja2026-09-14T09:39:44-07:00脂質代謝プロファイルが明らかにする、後毛細血管性と複合型肺高血圧の病態の違い https://news.medxy.ai/balancing-efficacy-and-safety-neoadjuvant-immunochemoradiotherapy-vs-immunochemotherapy-in-elderly-esophageal-squamous-cell-carcinoma/Medxy AIen2026-09-14T09:39:28-07:00Balancing Efficacy and Safety: Neoadjuvant Immunochemoradiotherapy vs. Immunochemotherapy in Elderly Esophageal Squamous Cell Carcinoma https://news.medxy.ai/vi/73433-2/Medxy AIvi2026-09-14T09:39:21-07:00脂質代謝プロファイルの違いが、毛細血管後性肺高血圧症と前・後毛細血管混合性肺高血圧症の病態生理学的差異を明らかにする https://news.medxy.ai/distinct-lipid-metabolic-profiles-unveil-pathophysiological-differences-between-postcapillary-and-combined-pre-and-postcapillary-pulmonary-hypertension/Medxy AIen2026-09-14T09:38:58-07:00Distinct Lipid Metabolic Profiles Unveil Pathophysiological Differences Between Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension https://news.medxy.ai/designing-cardiovascular-outcomes-trials-in-clonal-hematopoiesis-a-precision-medicine-imperative/Medxy AIen2026-09-14T09:37:21-07:00Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis: A Precision Medicine Imperative https://news.medxy.ai/zh/noninvasive-hf-diagnosis/Medxy AIzh2026-09-14T09:20:03-07:00优化射血分数保留型心力衰竭的无创诊断：结合左心房顺应性评估的增强型运动负荷超声心动图 https://news.medxy.ai/ja/73386-2/Medxy AIja2026-09-14T09:19:38-07:00駆出率保持性心不全の非侵襲的診断の最適化：左房コンプライアンス評価を組み合わせた強化型運動負荷心エコー法 https://news.medxy.ai/vi/73385-2/Medxy AIvi2026-09-14T09:19:15-07:00Tối ưu hóa chẩn đoán không xâm lấn suy tim phân suất tống máu bảo tồn: Siêu âm tim gắng sức cải tiến kết hợp đánh giá độ giãn nở nhĩ trái https://news.medxy.ai/refining-non-invasive-diagnosis-of-hfpef-enhanced-exercise-stress-echocardiography-with-left-atrial-compliance-assessment/Medxy AIen2026-09-14T09:18:54-07:00Refining Non-Invasive Diagnosis of HFpEF: Enhanced Exercise Stress Echocardiography with Left Atrial Compliance Assessment https://news.medxy.ai/zh/portugal-heart-failure/Medxy AIzh2026-09-14T09:18:17-07:00葡萄牙50岁及以上成年人心力衰竭现状：PORTHOS研究揭示患病率与主要表型 https://news.medxy.ai/ja/portugal-heart-failure-2/Medxy AIja2026-09-14T09:17:58-07:00ポルトガル50歳以上成人の心不全：PORTHOS研究が示した有病率と主要表現型の実態 https://news.medxy.ai/vi/heart-failure-porthos-study/Medxy AIvi2026-09-14T09:17:37-07:00Suy tim ở người Bồ Đào Nha từ 50 tuổi trở lên: Những phát hiện từ nghiên cứu PORTHOS về tỷ lệ hiện mắc và các kiểu hình chủ đạo https://news.medxy.ai/heart-failure-in-portuguese-adults-aged-50-and-above-insights-from-the-porthos-study-on-prevalence-and-predominant-phenotypes/Medxy AIen2026-09-14T09:17:18-07:00Heart Failure in Portuguese Adults Aged 50 and Above: Insights from the PORTHOS Study on Prevalence and Predominant Phenotypes https://news.medxy.ai/zh/73377-2/Medxy AIzh2026-09-14T09:16:37-07:00ALB单基因变异：一种与严重高胆固醇血症相关的新型遗传因素 https://news.medxy.ai/ja/73376-2/Medxy AIja2026-09-14T09:16:13-07:00ALB遺伝子バリアント：重度高コレステロール血症に関連する新たな遺伝的要因 https://news.medxy.ai/vi/alb-gene-variant/Medxy AIvi2026-09-14T09:15:48-07:00Biến thể đơn gen ALB: Yếu tố di truyền mới liên quan đến tăng cholesterol máu nặng https://news.medxy.ai/zh/left-atrial-staging/Medxy AIzh2026-09-14T09:14:33-07:00肥厚型心肌病中新发房颤的预测利器：生理性左心房分期 https://news.medxy.ai/ja/73373-2/Medxy AIja2026-09-14T09:14:14-07:00肥大型心筋症における新規発症心房細動の強力な予測ツール：生理学的左房病期分類 https://news.medxy.ai/vi/left-atrial-phases/Medxy AIvi2026-09-14T09:13:52-07:00Phân giai đoạn nhĩ trái sinh lý: Dấu ấn dự báo rung nhĩ mới khởi phát trong bệnh cơ tim phì đại https://news.medxy.ai/physiological-left-atrial-staging-as-a-predictor-of-new-onset-atrial-fibrillation-in-hypertrophic-cardiomyopathy/Medxy AIen2026-09-14T09:13:30-07:00Physiological Left Atrial Staging as a Predictor of New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy https://news.medxy.ai/zh/hnrnpk-lactylation-inflammation/Medxy AIzh2026-09-14T09:12:54-07:00代谢与剪接的交汇点：HNRNPK乳酰化驱动心肌缺血/再灌注中的炎症与损伤 https://news.medxy.ai/ja/hnrnpk-lactoylation/Medxy AIja2026-09-14T09:12:32-07:00代謝とスプライシングをつなぐ新機軸：HNRNPKラクトイル化が心筋虚血再灌流の炎症・障害を駆動する https://news.medxy.ai/vi/hnrnpk-inflammation/Medxy AIvi2026-09-14T09:12:09-07:00Nút giao chuyển hóa–nối cắt: Lactyl hóa HNRNPK thúc đẩy viêm và tổn thương trong thiếu máu cục bộ/tái tưới máu cơ tim https://news.medxy.ai/metabolic-splicing-nexus-hnrnpk-lactylation-drives-inflammation-and-injury-in-myocardial-ischemia-reperfusion/Medxy AIen2026-09-14T09:11:48-07:00Metabolic Splicing Nexus: HNRNPK Lactylation Drives Inflammation and Injury in Myocardial Ischemia/Reperfusion https://news.medxy.ai/ja/pembrolizumab-chemotherapy-cervical-cancer/Medxy AIja2026-09-14T09:11:11-07:00子宮頸がんに対するペムブロリズマブ＋化学療法：KEYNOTE-826無作為化臨床試験の5年探索的解析 https://news.medxy.ai/vi/pembrolizumab-cervical-cancer/Medxy AIvi2026-09-14T09:10:51-07:00Pembrolizumab phối hợp hóa trị trong ung thư cổ tử cung: phân tích thăm dò 5 năm từ thử nghiệm lâm sàng ngẫu nhiên KEYNOTE-826 https://news.medxy.ai/pembrolizumab-plus-chemotherapy-for-cervical-cancer-five-year-exploratory-analysis-from-the-keynote-826-randomized-clinical-trial/Medxy AIen2026-09-14T09:10:33-07:00Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial https://news.medxy.ai/ja/73360-2/Medxy AIja2026-09-14T09:09:54-07:00軟部組織および内臓平滑筋肉腫の管理に関する国際コンセンサス：平滑筋肉腫グローバル・コンセンサス・グループによる主要な推奨事項（2026年） https://news.medxy.ai/vi/leiomyosarcoma-guidelines/Medxy AIvi2026-09-14T09:09:13-07:00Đồng thuận quốc tế về quản lý sarcoma cơ trơn mô mềm và tạng: Các khuyến nghị chính từ Nhóm Đồng thuận Toàn cầu về Sarcoma cơ trơn (2026) https://news.medxy.ai/zh/soft-tissue-sarcoma-consensus/Medxy AIzh2026-09-14T09:08:34-07:00软组织与内脏平滑肌肉瘤管理国际共识：平滑肌肉瘤全球共识组关键建议（2026） https://news.medxy.ai/international-consensus-on-management-of-soft-tissue-and-visceral-leiomyosarcomas-key-recommendations-from-the-leiomyosarcoma-global-consensus-group-jama-oncology-2026/Medxy AIen2026-09-14T09:08:01-07:00International Consensus on Management of Soft Tissue and Visceral Leiomyosarcomas: Key Recommendations from the Leiomyosarcoma Global Consensus Group (2026)